Biotechnology News and Research

RSS

UIC receives federal contract to develop antibiotics against three bacterial infections

Researchers at the University of Illinois at Chicago's Center for Pharmaceutical Biotechnology have been awarded a federal contract for up to $13.8 million to develop antibiotics to treat anthrax, tularemia and plague.

28 Apr 2011

Adolor first quarter net loss decreases to $7.3 million

Adolor Corporation today reported net sales of ENTEREG® (alvimopan) were $7.5 million for the three months ended March 31, 2011, a 42% increase compared to net sales of $5.3 million for the three months ended March 31, 2010.

28 Apr 2011

Nautic Partners announces acquisition of Omnicare Clinical Research

Nautic Partners LLC, a private equity firm with more than $2.5 billion of capital under management, today announced that it has acquired Omnicare Clinical Research from Omnicare, Inc. Headquartered in King of Prussia, PA, Omnicare CR is a full-service, global clinical research organization.

28 Apr 2011

Blood levels of inflammation-controlling protein linked to childrens' risk of developing diabetes

Decreasing blood levels of a protein that helps control inflammation may be a red flag that could help children avoid type 1 diabetes, researchers say.

28 Apr 2011

Simple home genetic test can identify health risk factors in young athletes

It's a simple home genetic test, but the results it produces can make workouts more effective, children's sports choices more appropriate and trainers' awareness of potential risk factors more precise.

28 Apr 2011

The Lancet publishes phase 3 clinical study data on VIVITROL for treatment of opioid dependence

Alkermes, Inc. today announced that results from the phase 3 clinical study of VIVITROL® (naltrexone for extended-release injectable suspension) in opioid dependence have been published by The Lancet. The six-month, phase 3 trial met its primary endpoint and showed significantly greater opioid-free weeks among patients treated with VIVITROL, compared to placebo.

28 Apr 2011

Affymetrix reports total revenue of $73.7 million for first quarter 2011

Affymetrix, Inc., today reported its operating results for the first quarter of 2011. Total revenue for the quarter was $73.7 million, as compared to total revenue of $80.2 million in the first quarter of 2010.

28 Apr 2011

ProtoKinetix, Imaginative Research Associates partner to formulate topical anti-inflammation product

ProtoKinetix, is pleased to announce, that it has entered into a Joint Venture Agreement with Imaginative Research Associates, Inc. to formulate a topical anti-inflammation product for the skin care market.

27 Apr 2011

Biomagnetics accepts Los Alamos National Labs' optical biosensor for disease diagnosis

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, cholera and malaria detection, and other innovative technologies, today announced it has accepted delivery of the world's first integrated optical biosensor for disease diagnosis.

27 Apr 2011

LSP announces initial public offering of Life Sciences Fund on NYSE Euronext

LSP Advisory B.V., a group company of LSP, one of Europe's largest and most reputable specialized healthcare and biotechnology investment firms, today announced the initial public offering of the LSP Life Sciences Fund N.V. on NYSE Euronext Amsterdam.

27 Apr 2011

EPO grants patent to Microbix' VIRUSMAX vaccine enhancement technology

Microbix Biosystems Inc., a biotechnology company commercializing novel technologies to enhance vaccine production yields, and other innovative biologics, announced today that the European Patent Office recently granted patent protection for the company's proprietary VIRUSMAX technology, which is designed to increase influenza vaccine yields and has demonstrated an average yield increase of at least two-fold over current vaccine production methods.

27 Apr 2011

Blueberries may help fight obesity

Recently a study out of the Texas Women's University looked at whether blueberries with their high polyphenol content could help in fighting obesity. Blueberries after all have already been cited as having positive health effects on other conditions like cardiovascular disease and metabolic syndrome. The study was conducted in Petri dishes (not live animals) using a blueberry polyphenol extract and tissue cultures from mice.

27 Apr 2011

Rxi secures SBIR grants to develop novel RNAi therapeutics for ALS

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that it was awarded two Small Business Innovation Research grants from the National Institutes of Health.

27 Apr 2011

PPD reports net revenue of $383.2 million for first quarter 2011

PPD, Inc. today reported its financial and operating results for the first quarter ended March 31, 2011.

27 Apr 2011

FDA clears Biomet's Active Articulation Hip System

Biomet, Inc., a global leader in the manufacture of orthopedic and biotechnology products, today announced clearance of its Active Articulation E1 Dual Mobility Hip System, by the United States Food and Drug Administration.

27 Apr 2011

PolyMedix defensin-mimetic antibiotic compounds show antimicrobial efficacy against anthrax

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat patients with acute infectious diseases and cardiovascular disorders, announced today that several of its defensin-mimetic antibiotic compounds have shown antimicrobial efficacy in an animal model against the bacteria that causes anthrax.

26 Apr 2011

BIOBASE introduces new genome sequence custom annotation tool

BIOBASE announced its launch of a new custom annotation tool designed to aid in functional annotation of next generation sequences from uncharacterized genomes.

26 Apr 2011

HemaQuest initiates HQK-1001 Phase 2 study in sickle cell disease

HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that clinical investigators have enrolled the first patient in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease.

26 Apr 2011

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.

From QIAGEN Manchester Limited 25 Apr 2011

New book on aging

Aging is a natural part of life. From the minute we are born we are heading in one certain direction: towards death. That said, it is possible to arrive at that ultimate destination graceful and vital to our last days rather than chronically ill suffering from one or many debilitating illnesses.

25 Apr 2011